Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies
- 30 May 2003
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (12) , 1018-1025
- https://doi.org/10.1038/sj.gt.3301962
Abstract
The -folate receptor (FR) is selectively overexpressed in 90% of nonmucinous ovarian carcinomas, whereas no expression is detectable in normal ovarian surface epithelium (OSE). Indirect evidence suggests that FR expression is associated with tumor progression and affects cell proliferation. To evaluate better the role of FR, we developed an approach based on intracellular expression of single-chain (sc) antibodies (intrabody) to downmodulate membrane expression of FR in ovary cancer cells. IGROV-1 and SKOV3 ovarian carcinoma cell lines were transfected with an anti-FR intrabody. Transfectants and parental cells were tested for FR, integrins and anti-FR intrabody expression by fluorescence-activated cell sorting (FACS), reverse transcription and polymerase chain reaction (RT-PCR) and/or immunoblotting. Cell growth characteristics and adhesion properties were evaluated in liquid, semisolid and organotypic cultures. The anti-FR scFv inhibited FR expression from 60 to 99%. At physiological concentrations of folate, proliferation varied directly as a function of FR expression. FR downmodulation was accompanied by reduced colony-forming ability in soft agar, morphological change of the cells, significant enhanced adhesion to laminin or Matrigel, a two- to three-fold increase in 64 integrin expression, and a marked reduction in laminin production. In three-dimensional organotypic cultures, anti-FR intrabody-transfected IGROV1 cells grew as a single-ordered layer, reminiscent of normal OSE growth in vivo. In conclusion, the anti-FR intrabody reverses the transformed phenotype in ovary cancer cells and may provide an efficient means to inhibit selectively the growth of these cells.Keywords
This publication has 35 references indexed in Scilit:
- Clinical trials of antibody therapyImmunology Today, 2000
- A role for intracellular immunization in chemosensitization of tumor cells?Gene Therapy, 1999
- Intracellular Antibodies Against HIV-1 Envelope Protein for AIDS Gene Therapy. Dana Farber Cancer Institute, Boston, MassachusettsHuman Gene Therapy, 1998
- Overexpression of folate binding protein in ovarian cancersInternational Journal of Cancer, 1997
- Targeted Tumor Cytotoxicity Mediated by Intracellular Single-Chain Anti-oncogene AntibodiesPublished by Elsevier ,1997
- Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implicationsCancer, 1994
- Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.Proceedings of the National Academy of Sciences, 1993
- The Ca-MOv18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositolBiochemical and Biophysical Research Communications, 1990
- Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol.Journal of Clinical Investigation, 1989
- Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificityInternational Journal of Cancer, 1987